<DOC>
	<DOCNO>NCT01416428</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , activity , safety oprozomib patient hematologic malignancy .</brief_summary>
	<brief_title>Open-label Study Safety Activity Oprozomib Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>INCLUSION CRITERIA : Phase 1b Histologically confirm diagnosis hematologic malignancy , exclude patient acute leukemia MDS . Relapsed standard therapy malignancy consider appropriate candidate Phase 1 clinical study treat physician . Phase 2 Multiple myeloma measurable disease Waldenstr√∂m macroglobulinemia symptomatic relapse Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . Ethical/Other Patients must sign write informed consent form accordance federal , local , institutional guideline . Female patient childbearing potential must negative serum urine pregnancy test agree use effective contraception . Male patient must use effective barrier method contraception . EXCLUSION CRITERIA : Chemotherapy approve investigational anticancer therapeutic , include steroid therapy intend treat underlie malignancy , within 3 week prior first dose 6 week antibody therapy . Radiation therapy within 3 week prior first dose . Radioimmunotherapy within 8 week prior first dose . Localized radiation therapy within 1 week prior first dose . Immunotherapy within 3 week prior first dose ( except antibody therapy , 6 week require ) . Prior stem cell transplant ( SCT ) therapy ( autologous SCT within prior 8 week ; allogeneic SCT within prior 16 week ) . Patients prior allogeneic SCT evidence moderatetosevere graftvshost disease ( GvHD ; define Filipovich 2005 ) . Evidence central nervous system ( CNS ) lymphoma . Prior treatment carfilzomib unless phase 2 . Major surgery within 3 week prior first dose . Symptomatic Congestive heart failure , ischemia , conduction abnormality , myocardial infarction within 6 month . Acute active infection require systemic antibiotic , antiviral , antifungal . Known suspect human immunodeficiency virus ( HIV ) infection patient HIV seropositive . Active hepatitis A , B , C infection . Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose . Patients pleural effusion require routine thoracentesis ascites require routine paracentesis . History previous clinically significant GI bleed last 6 month prior first dose . Female patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>waldenstrom macroglobulinemia</keyword>
</DOC>